NeuroNEXT News

NN102 SPRINT-MS top-line results achieve primary endpoints

External Source: 

MediciNova, the industry sponsor of NN102 SPRINT-MS, announced the positive top-line results from the trial. The second funded NeuroNEXT trial, a study to evaluate the activity, safety, and tolerability of Ibudilast in patients with Multiple Sclerosis (MS), has very promising results for MS treatment. Results indicate that Ibudilast demonstrated a statistically significant reduction in the rate of progression of whole brain atrophy as compared to placebo.

February 2012 issue of The Lancet Neurology praises formation of NeuroNEXT

External Source: 

Article Summary: In February, 2012, the US National Institute for Neurological Disorders and Stroke (NINDS) is due to announce the first study to be supported by the National Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). With this ambitious new network, NINDS aims to facilitate the progress of new drugs from the laboratory to the clinic, specifically at the stage of phase 2 trials and biomarker validation studies. New therapies for neurological diseases are undoubtedly needed, but how can NeuroNEXT make a difference?

NeuroNEXT U01 funding announcement

Please visit the NIH page for information related to the NeuroNEXT Clinical Trials (U01 Clinical Trial Optional) funding mechanism.  The FOA is available for applications beginning January 5, 2018, through January 8, 2021.